Salona Global Medical Device (TSE:EVMT) has released an update.
Evome Medical Technologies has reported a positive second quarter in 2024 with a significant increase in Adjusted EBITDA, a rise in revenues from its core Biodex division, and a substantial reduction in debt. Under the leadership of CEO Mike Seckler, the company has seen a turnaround with successful restructuring, focusing on sales growth and cost management, and is optimistic about its future financial momentum.
For further insights into TSE:EVMT stock, check out TipRanks’ Stock Analysis page.
